Contribution of clinical information to the predictive performance of plasma β-amyloid levels for amyloid positron emission tomography positivity

Frontiers in Aging Neuroscience

Aging Neuroscience

José Antonio Allué¹  Sergio Castillo¹  María Pascual-Lucas¹  Leticia Sarasa¹  John Gallacher²  Duk L. Na³  Hee Jin Kim⁴  Sang Won Seo⁵  Jun Pyo Kim⁶  Min Young Chun⁷  Hyemin Jang⁸ 

[1]Araclon Biotech-Grifols, Zaragoza, Spain

[2]Department of Psychiatry, Warneford Hospital, University of Oxford, Oxford, United Kingdom

[3]Departments of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea

[4]Alzheimer's Disease Convergence Research Center, Samsung Medical Center, Seoul, Republic of Korea

[5]Departments of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea

[6]Alzheimer's Disease Convergence Research Center, Samsung Medical Center, Seoul, Republic of Korea

[7]Department of Health Sciences and Technology, SAIHST, Sungkyunkwan University, Seoul, Republic of Korea

[8]Department of Digital Health, SAIHST, Sungkyunkwan University, Seoul, Republic of Korea

[9]Departments of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea

[10]Alzheimer's Disease Convergence Research Center, Samsung Medical Center, Seoul, Republic of Korea

[11]Department of Health Sciences and Technology, SAIHST, Sungkyunkwan University, Seoul, Republic of Korea

[12]Department of Digital Health, SAIHST, Sungkyunkwan University, Seoul, Republic of Korea

[13]Department of Clinical Research Design and Evaluation, SAIHST, Sungkyunkwan University, Seoul, Republic of Korea

[14]Departments of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea

[15]Center for Neuroimaging, Radiology and Imaging Sciences, Indiana University School of Medicine, Indianapolis, IN, United States

[16]Departments of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea

[17]Department of Neurology, Yonsei University College of Medicine, Seoul, Republic of Korea

[18]Department of Neurology, Yongin Severance Hospital, Yonsei University Health System, Yongin, Republic of Korea

[19]Departments of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea

[20]Neuroscience Center, Samsung Medical Center, Seoul, Republic of Korea

[21]Alzheimer's Disease Convergence Research Center, Samsung Medical Center, Seoul, Republic of Korea

关键词: Alzheimer’s disease;    β-Amyloid;    positron emission tomography;    cerebrospinal fluid;    plasma;    apolipoprotein E;   

DOI  :  10.3389/fnagi.2023.1126799

 received in 2022-12-18, accepted in 2023-02-24,  发布年份 2023

来源: Frontiers

【 摘 要 】

BackgroundEarly detection of β-amyloid (Aβ) accumulation, a major biomarker for Alzheimer’s disease (AD), has become important. As fluid biomarkers, the accuracy of cerebrospinal fluid (CSF) Aβ for predicting Aβ deposition on positron emission tomography (PET) has been extensively studied, and the development of plasma Aβ is beginning to receive increased attention recently. In the present study, we aimed to determine whether APOE genotypes, age, and cognitive status increase the predictive performance of plasma Aβ and CSF Aβ levels for Aβ PET positivity.MethodsWe recruited 488 participants who underwent both plasma Aβ and Aβ PET studies (Cohort 1) and 217 participants who underwent both cerebrospinal fluid (CSF) Aβ and Aβ PET studies (Cohort 2). Plasma and CSF samples were analyzed using ABtest-MS, an antibody-free liquid chromatography-differential mobility spectrometry-triple quadrupole mass spectrometry method and INNOTEST enzyme-linked immunosorbent assay kits, respectively. To evaluate the predictive performance of plasma Aβ and CSF Aβ, respectively, logistic regression and receiver operating characteristic analyses were performed.ResultsWhen predicting Aβ PET status, both plasma Aβ42/40 ratio and CSF Aβ42 showed high accuracy (plasma Aβ area under the curve (AUC) 0.814; CSF Aβ AUC 0.848). In the plasma Aβ models, the AUC values were higher than plasma Aβ alone model, when the models were combined with either cognitive stage (p < 0.001) or APOE genotype (p = 0.011). On the other hand, there was no difference between the CSF Aβ models, when these variables were added.ConclusionPlasma Aβ might be a useful predictor of Aβ deposition on PET status as much as CSF Aβ, particularly when considered with clinical information such as APOE genotype and cognitive stage.

【 授权许可】

Unknown   
Copyright © 2023 Chun, Jang, Kim, Kim, Gallacher, Allué, Sarasa, Castillo, Pascual-Lucas, Na, Seo and on behalf of DPUK.